Form 4: Dare Bioscience CAO Granted 49,000 Stock Options

Dare Bioscience's Chief Accounting Officer, MarDee Haring-Layton, was granted 49,000 employee stock options with an exercise price of $1.81.

Summary

• MarDee Haring-Layton, Chief Accounting Officer of Dare Bioscience, Inc. (DARE), was granted 49,000 employee stock options.
• The options have an exercise price of $1.81 per share.
• The grant date for these options was January 30, 2026.
• The options will vest in 48 equal monthly installments, beginning one month after the grant date.
• The expiration date for these options is January 30, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents standard executive compensation and aligns management incentives, without providing new operational or financial performance data.

Positives

• Granting of stock options aligns management's interests with shareholder value creation.
• The options have a 10-year expiration period, providing a long-term incentive for the Chief Accounting Officer.

Negatives

• No immediate negative financial impact is evident from this Form 4 filing.

Risks

• The value of the options is dependent on the future stock price of Dare Bioscience, Inc. exceeding the exercise price of $1.81.
• Vesting is subject to continuous service, meaning the options could be forfeited if the reporting person leaves the company.

Future Outlook

The granting of these options indicates a long-term incentive for the Chief Accounting Officer, aligning her future financial interests with the company's stock performance over the next decade, subject to continued employment.

Industry Context

StockSavvy.ai notes that equity compensation, such as stock options, is a standard practice in the biotechnology and pharmaceutical sectors to attract, retain, and motivate key executives. This grant is consistent with typical compensation structures designed to incentivize long-term performance and align executive interests with shareholder value.

Comparison to Industry Standards

• The grant of 49,000 options to a Chief Accounting Officer is within the typical range for a company of Dare Bioscience's size and stage in the biotech industry, though specific comparisons would require detailed compensation peer group analysis.
• An exercise price of $1.81, likely the market price on the grant date, is standard for employee stock options to ensure they provide future incentive.
• A 10-year expiration period is a common industry standard for employee stock options, similar to grants seen at companies like BioNTech or Moderna for non-executive roles, providing ample time for value realization.

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also potential benefit from incentivized management performance.
• Employees: This grant is specific to the Chief Accounting Officer; no direct impact on other employees is noted, though it reflects the company's compensation strategy.

Next Steps

• The options will begin vesting in 48 equal monthly installments starting one month after January 30, 2026.
• The Chief Accounting Officer may exercise these options once they vest and before the expiration date of January 30, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of employee stock options to a key executive. While it aligns management's interests with shareholders, it does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate, maintaining current positions while awaiting more substantive updates.

Keywords

Dare Bioscience, DARE, Stock Option, Insider Transaction, Form 4, Equity Compensation, MarDee Haring-Layton, Chief Accounting Officer